Invicorp

Phentolamine Mesilate, the active ingredient in Invicorp, is an alpha‑adrenergic antagonist presented as an injectable for intracavernous use. It, together with the vasoactive intestinal peptide analog aviptadil, is used to improve penile blood flow in men with erectile dysfunction. The combination works by causing smooth‑muscle relaxation and enhanced arterial inflow to the corpus cavernosum, supporting erection in patients who have not responded adequately to oral therapy.

GNH USA supplies Invicorp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Invicorp is indicated for conditions affecting penile vascular function and erectile capacity. It acts on the alpha‑adrenergic and VIP pathways to restore adequate blood flow.

- Erectile dysfunction: improves penile blood flow to achieve and maintain an erection suitable for sexual activity. - Penile vasculogenic insufficiency: restores vascular tone and smooth‑muscle relaxation in cases of reduced arterial inflow. - Post‑prostatectomy erectile dysfunction: assists men recovering from surgery by enhancing intracavernous perfusion.

Adverse reactions may occur following intracavernous injection of Invicorp. Patients should be informed of both common and serious possibilities.

Common Side Effects: - Penile pain or discomfort at the injection site. - Bruising or hematoma formation. - Transient headache. - Flushing or warmth sensation. - Mild hypotension. - Priapism lasting less than four hours.

Serious or Rare Side Effects: - Prolonged erection (>4 hours) requiring medical intervention. - Severe hypotension leading to dizziness or syncope. - Allergic reaction with rash, itching, or swelling. - Infection at the injection site. - Cardiovascular events such as myocardial ischemia. - Hematuria or urinary retention.

Before using Invicorp, clinicians should consider several safety measures. - Cardiovascular assessment: evaluate for unstable heart disease before administration. - Nitrate use: avoid concurrent use with nitrates or nitric‑oxide donors. - Blood pressure monitoring: observe for sudden drops in systemic pressure. - Aseptic technique: ensure sterile injection to prevent infection. - Priapism education: advise patients to seek immediate care if erection persists beyond four hours. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Invicorp may interact with other agents that influence vascular tone or coagulation.

Major Interactions (Avoid): - Nitrates (e.g., nitroglycerin): additive vasodilatory effect can cause severe hypotension. - Alpha‑adrenergic blockers (e.g., prazosin): may amplify blood‑pressure lowering. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): risk of excessive penile blood flow and priapism.

Moderate Interactions (Monitor Closely):\n- Antihypertensive agents (e.g., ACE inhibitors, beta‑blockers): monitor blood pressure for additive effects. - Anticoagulants or antiplatelet drugs (e.g., warfarin, aspirin): watch for increased bleeding at injection site. - Drugs affecting platelet function (e.g., clopidogrel): may enhance hematoma formation.